{"address1": "1 Ashley Road", "address2": "3rd Floor", "city": "Altrincham", "zip": "WA14 2DT", "country": "United Kingdom", "website": "https://www.centessa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.", "fullTimeEmployees": 77, "companyOfficers": [{"maxAge": 1, "name": "Dr. Saurabh  Saha M.D., Ph.D.", "age": 48, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1041809, "exercisedValue": 0, "unexercisedValue": 6715049}, {"maxAge": 1, "name": "Mr. John J. Crowley CPA", "age": 50, "title": "CFO and Principal Financial & Accounting Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tia L. Bush", "age": 53, "title": "Chief Technology & Quality Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen K. Sheppard Esq., J.D.", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iqbal J. Hussain L.L.B.", "age": 43, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen M. Anderson", "age": 56, "title": "Chief People Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gregory M. Weinhoff M.B.A., M.D.", "age": 53, "title": "Chief Business Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 655004, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mario Alberto Accardi Ph.D.", "title": "President of the Orexin Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ellie  Im M.D.", "title": "Senior Vice President of Clinical Development & Oncology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Charlene  Stoudt", "title": "Senior Vice President of Clinical Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 14.38, "open": 14.34, "dayLow": 13.01, "dayHigh": 14.34, "regularMarketPreviousClose": 14.38, "regularMarketOpen": 14.34, "regularMarketDayLow": 13.01, "regularMarketDayHigh": 14.34, "payoutRatio": 0.0, "beta": 1.548, "forwardPE": -7.7368417, "volume": 1380037, "regularMarketVolume": 1380037, "averageVolume": 912583, "averageVolume10days": 1073480, "averageDailyVolume10Day": 1073480, "bid": 10.23, "ask": 16.71, "bidSize": 1, "askSize": 1, "marketCap": 1762024320, "fiftyTwoWeekLow": 7.75, "fiftyTwoWeekHigh": 19.09, "fiftyDayAverage": 16.3838, "twoHundredDayAverage": 14.700525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1397680000, "profitMargins": 0.0, "floatShares": 91689433, "sharesOutstanding": 133184000, "sharesShort": 4864841, "sharesShortPriorMonth": 4153707, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0365, "heldPercentInsiders": 0.0154, "heldPercentInstitutions": 0.9614, "shortRatio": 4.53, "shortPercentOfFloat": 0.0432, "impliedSharesOutstanding": 133184000, "bookValue": 3.028, "priceToBook": 4.3692203, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -235756992, "trailingEps": -2.06, "forwardEps": -1.71, "enterpriseToEbitda": -6.964, "52WeekChange": 0.22273564, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 13.23, "targetHighPrice": 38.0, "targetLowPrice": 26.0, "targetMeanPrice": 31.25, "targetMedianPrice": 30.5, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 482176992, "totalCashPerShare": 3.62, "ebitda": -200712992, "totalDebt": 117828000, "quickRatio": 9.095, "currentRatio": 9.249, "debtToEquity": 29.344, "returnOnAssets": -0.2682, "returnOnEquity": -0.73929, "freeCashflow": -75189624, "operatingCashflow": -142055008, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "CNTA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Centessa Pharmaceuticals plc", "longName": "Centessa Pharmaceuticals plc", "preMarketChange": 0.77000046, "preMarketChangePercent": 5.8201094, "preMarketPrice": 14.0, "regularMarketChange": -1.1500006, "regularMarketDayRange": "13.01 - 14.34", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 912583, "fiftyTwoWeekLowChange": 5.4799995, "fiftyTwoWeekLowChangePercent": 0.7070967, "fiftyTwoWeekRange": "7.75 - 19.09", "fiftyTwoWeekHighChange": -5.8600006, "fiftyTwoWeekHighChangePercent": -0.30696702, "fiftyTwoWeekChangePercent": 22.273563, "epsTrailingTwelveMonths": -2.06, "epsForward": -1.71, "epsCurrentYear": -1.512, "priceEpsCurrentYear": -8.75, "fiftyDayAverageChange": -3.153801, "fiftyDayAverageChangePercent": -0.19249508, "twoHundredDayAverageChange": -1.4705257, "twoHundredDayAverageChangePercent": -0.10003219, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-05-28", "prevName": "Centessa Pharmaceuticals Limited", "nameChangeDate": "2025-04-01", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1622208600000, "regularMarketChangePercent": -7.9972224, "regularMarketPrice": 13.23, "corporateActions": [], "preMarketTime": 1743580972, "regularMarketTime": 1743537601, "exchange": "NMS", "messageBoardId": "finmb_704505677", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "displayName": "Centessa Pharmaceuticals", "trailingPegRatio": null}